American Society Of Addiction Medicine Inc.

American Society of Addiction Medicine Inc., a tax-exempt nonprofit professional medical society based in Rockville, Maryland, receives federal grant funding and small purchase orders as a prime recipient to deliver addiction medicine training, clinical practice guidelines, and technical assistance programs to healthcare professionals. ASAM competes in the full-and-open market without set-aside designations and operates primarily as a grant recipient rather than a contract prime, with 38 of 39 recent awards classified as prime work (97%) and only one grant sub-award.

ASAM's federal customer base concentrates within the Department of Health and Human Services (HHS) ecosystem. The top five customer agencies by award count account for 46% of awards and include the National Institute on Drug Abuse (5 awards, $25 thousand combined potential value), the National Institute of Child Health and Human Development (4 awards, $75 thousand), the Substance Abuse and Mental Health Services Administration (3 awards), the Program Support Center (3 awards), and the HHS Office of the Assistant Secretary for Administration (3 awards, $405 thousand). By potential value, the Office of the Assistant Secretary for Administration leads at $405 thousand across three awards, followed by the Centers for Disease Control and Prevention Pittsburgh ($225 thousand) and the National Institute of Child Health and Human Development ($75 thousand). ASAM's contract vehicle footprint is sparse; recent work consists primarily of small purchase orders and grants rather than placement on multi-year IDIQs or GWACs.

Recent capability work includes a $2.999 million three-year project grant from SAMHSA's Center for Substance Abuse Treatment (awarded September 2026, performance through September 2029) to implement the Providers Clinical Support System — Substance Use Disorder Treatment (PCSS-SUD Treatment), a national training and technical assistance program designed to deliver evidence-based substance use disorder prevention, treatment, and recovery services to at least 115,000 healthcare and counseling professionals through live and on-demand education, ECHO sessions, and implementation academies. A prior $25 thousand firm-fixed-price purchase order from the National Institute of Child Health and Human Development (July 2024) funded ASAM's annual addiction medicine training conference in Baltimore. ASAM also holds a cooperative agreement with the FDA's Center for Drug Evaluation and Research (awarded September 2022, completion August 2026) to develop national practice guidelines for safe benzodiazepine tapering, addressing overdose risk and inappropriate prescribing patterns.

Activity is sparse and uneven — two awards in 2021, two in 2022, one in 2023, two in 2024, and one in 2026 — with combined potential value of $788 thousand across all 39 awards. However, obligated dollars ($22.5 million) far exceed potential value, indicating that ASAM's federal grants carry multi-year performance periods with substantial cumulative funding despite small ceiling values per individual award record. ASAM holds one grant sub-award under the National Council for Behavioral Health, where it provides subject matter expertise and technical assistance on substance use disorder training for the CCBHC-E National Training and Technical Assistance Center (awarded October 2024). ASAM's organizational profile as a membership society with over 7,000 addiction medicine physicians and clinicians positions it as the federal government's primary subject-matter expert on addiction medicine education and guideline development, with HHS agencies routing clinical training and workforce capacity-building work through ASAM as a trusted nonprofit authority rather than through commercial contractors.